Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $16.88.

Several equities analysts have recently issued reports on FOLD shares. Jefferies Financial Group started coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $18.00 price target on the stock. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday. Morgan Stanley reissued an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Bank of America upped their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Finally, Cantor Fitzgerald boosted their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 30,401 shares of company stock valued at $339,363. Company insiders own 2.20% of the company's stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics during the third quarter worth approximately $26,000. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. raised its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in Amicus Therapeutics during the third quarter worth about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics during the third quarter worth about $55,000.

Amicus Therapeutics Stock Performance

FOLD traded up $0.07 during trading on Friday, reaching $9.80. 4,077,524 shares of the company were exchanged, compared to its average volume of 2,724,375. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The stock has a market cap of $2.93 billion, a P/E ratio of -28.82 and a beta of 0.60. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The firm has a 50 day moving average of $10.48 and a 200 day moving average of $10.61.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.